secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2025-02-24T23:59:59+00:00
Accession:  0000950170-25-025227
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA declines Invivyd's request to expand PEMGARDA EUA to COVID-19 treatment; prophylaxis EUA unchanged
--------------------------------------------------------------------------------

- FDA declined expansion of PEMGARDA EUA for mild-to-moderate COVID-19 treatment in immunocompromised patients with no alternative options.
- FDA reasoning: immunobridging must show superior antiviral activity, not just equivalence, to prior mAbs like adintrevimab.
- Invivyd provided data showing comparable antiviral activity and predicted clinical efficacy above convalescent plasma.
- Existing PEMGARDA EUA for pre-exposure prophylaxis remains in effect; treatment opportunity not in prior financial guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000095017025025227/0000950170-25-025227-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000095017025025227/ivvd-20250221.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-025227

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer